Allergan plc markets products that provide treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business. The company was founded in 1983 and is based in Parsippany, New Jersey.
AGN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for AGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Allergan plc ranked in the 72th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 135.5%. As for the metrics that stood out in our discounted cash flow analysis of Allergan plc, consider:
As a business, AGN is generating more cash flow than 94.04% of positive cash flow stocks in the Healthcare.
Allergan plc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
Allergan plc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -5.54. This coverage rate is greater than that of just 7.84% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Allergan plc? See NVO, JAZZ, BLFS, HUM, and FMS.